An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.
about
Developing Biosensors in Developing Countries: South Africa as a Case StudyAptamers in diagnostics and treatment of viral infectionsUse of Aptamers as Diagnostics Tools and Antiviral Agents for Human VirusesStabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoproteinUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinSelection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsThe Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.Aptamer-targeted cell-specific RNA interferenceAptamers in virology: recent advances and challenges.Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer.Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.Cell-specific aptamer-mediated targeted drug deliveryDual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibitionAn aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus.UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CAptamers for Targeted Drug DeliveryNonantibody-based recognition: alternative molecules for detection of pathogens.Gene therapy progress and prospects: RNA aptamers.Therapeutic applications of aptamers.Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsNovel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.Aptamer-based therapeutics: new approaches to combat human viral diseasesAptamers and aptamer targeted delivery.Intracellular delivery of RNA-based therapeutics using aptamers.Characterisation of aptamers for therapeutic studies.Application of aptamers for targeted therapeutics.Aptamers: multifunctional molecules for biomedical research.Bridging the past and the future of virology: surface plasmon resonance as a powerful tool to investigate virus/host interactions.Efficient suppression of biofilm formation by a nucleic acid aptamer.Cell-specific aptamers as emerging therapeutics.Aptamers against pathogenic microorganisms.Aptamers: novel molecules as diagnostic markers in bacterial and viral infections?Aptamers in HIV research diagnosis and therapy.
P2860
Q26768606-C7E60FB7-5F73-4A3C-9D2F-4B1B77D0446DQ27014527-81AA9E53-56A6-4F61-9423-DD26C0BCA396Q28079654-5DEFE617-58D3-4470-A9DF-6C7F5EA41301Q28534454-9FB628E1-1698-4C6C-8BB7-7638DEF13270Q28730561-F8CC9F86-A039-484F-B8E7-EF40B1FAC6E4Q28732438-B78E28A0-56B6-4765-9A87-CB02CBBB75B5Q30859838-76BE4F61-D0CF-4E7A-B0B5-5AD202444802Q33470044-0F5006C7-65B8-42E4-9AA1-E6230A8E7A18Q33717239-FC39BBE2-D881-4ED7-9AFC-8251BE4F4C2EQ34162383-B03A6E40-46C2-4EAC-A069-71A89F9BC4DDQ34232003-49D90A42-10FE-4B85-8CA5-8CB268B58F2CQ34362343-86DE212B-159F-4D88-986F-5F7273FE36FAQ34509294-CBE4F707-F8EA-4667-BAFD-3D6BB324134DQ34599718-74349131-ECB1-4F16-9365-1156568661A0Q35024012-24321E4E-81B4-4181-9535-9017E964ED71Q35234289-7E730974-485F-436E-83F2-2FA7843F9E67Q35634404-0ADC868E-6060-425D-B311-CAC733866BB8Q35943810-3FE82C66-5097-483E-A333-96AD40E55A51Q36155891-035BE976-E3C5-487E-AB99-119199CB2B8EQ36641466-558F9427-F62D-4BE7-B311-80987F94BB51Q36728599-257260F8-B4EF-409C-8C3A-93455BF01E53Q37038988-B54EFBC2-5B77-42DB-A255-F1FA4EA3EA6FQ37247615-9113902E-9FB8-4B8E-9A9D-712683C8855EQ37305770-F775B617-F41B-4EE7-9F7A-D1ACBF5F580DQ37415958-35E01AA4-2190-4EF9-AE84-F97033FAD7B0Q37490756-0602D0AB-A64A-402B-99B9-85DC47F1B55CQ37885186-92068C88-77E1-4B68-830F-F0E15F1BF76BQ38089865-D911009E-B0FC-4B0E-AE7F-F40164739E37Q38096870-5609301E-CCF8-4E2D-9F3C-F5EED00B0FF8Q38138814-38733ECC-BEBD-49C9-9B44-7BAF20C1167BQ38141148-85F6FB71-52DB-45AE-ADB4-97F95EBE26E1Q38298638-C2A6F7B4-6C5F-41A0-B67B-C126799EFC44Q38302347-96EA616B-B394-4F0C-8A6F-A4C36F592DF7Q38563672-4DD9AA6C-919C-4EB2-8F1B-6E8CE08E7CE2Q42181807-B9F364E2-CCA2-4239-9850-E30786BA77A9Q50066811-E0545498-47EB-4C27-8F07-836CD3A97CAD
P2860
An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@ast
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@en
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@nl
type
label
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@ast
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@en
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@nl
prefLabel
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@ast
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@en
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@nl
P2093
P2860
P1433
P1476
An aptamer that neutralizes R5 ...... blocks gp120-CCR5 interaction.
@en
P2093
Antu K Dey
Makobetsa Khati
Richard Wyatt
P2860
P304
13806-13810
P356
10.1128/JVI.79.21.13806-13810.2005
P407
P577
2005-11-01T00:00:00Z